Retatrutide, Prader-Willi and 100 kg Lost

A case report published in JCEM Case Reports in September 2026 describes a 29-year-old man with genetically confirmed Prader-Willi syndrome who lost 108.7 kg, about 59% of his starting body weight, over 18 months on a sequence of three incretin-based medicines. He started at 185 kg with a body mass index of 59.7, plus a new diagnosis of type 2 diabetes. By the end of the 18 months, his diabetes was in remission and he had stopped all glucose-lowering medication.^[1]

What the case report describes

The patient had maternal uniparental disomy, one of the genetic mechanisms behind Prader-Willi syndrome (PWS), a rare disorder in which the brain's hunger-signaling circuitry does not register fullness the way it does in most people. His clinicians started him on retatrutide, the investigational triple receptor agonist that activates GLP-1, GIP and glucagon receptors at once, alongside a structured diet and exercise plan.^[1]

When retatrutide was stopped, the case report says the patient was switched to oral semaglutide and later to dulaglutide, both approved GLP-1 receptor agonists, continuing the same diet and exercise support. The authors describe only mild, transient gastrointestinal symptoms during dose escalation and no serious adverse events across the full 18 months. Neither the case report nor the underlying record specifies the exact doses used at each stage of the sequence, only that treatment moved from retatrutide to oral semaglutide to dulaglutide over the study window.^[1]

Why Prader-Willi syndrome makes this notable

PWS affects roughly 1 in 10,000 to 30,000 births and results from the loss of paternally active genes in a specific region of chromosome 15, most often a deletion or, as in this patient, maternal uniparental disomy. The hallmark is hyperphagia: an intense, hypothalamus-driven drive to eat that does not resolve with a full stomach. Standard management leans on strict calorie control, supervised exercise and growth hormone therapy to protect lean mass, and durable weight loss is rarely achieved.^[2]

Incretin-based drugs are not part of that standard playbook. The reference literature on PWS management does not mention GLP-1 or GIP receptor agonists at all, which is part of why a single favorable case draws attention: it is testing a drug class in a condition it was never developed for, against a form of hunger that has a different biological driver than the hunger seen in typical obesity. Tirzepatide and other dual or triple agonists in the same drug family have not been reported in PWS case literature at this scale, which is part of what makes this single result stand out.^[2]

How the numbers compare with controlled trial data

The 59% weight loss in this case is far larger than what retatrutide has shown in controlled trials of general obesity. In the Phase 2 trial of 338 adults without PWS, the 12 mg weekly dose produced a mean 24.2% body-weight reduction at 48 weeks, with 83% of that group reaching at least 15% weight loss. The 8 mg dose produced 22.8%, the 4 mg dose 17.1%, and the 1 mg dose 8.7%, against 2.1% on placebo.^[3]

That gap does not mean retatrutide works better in Prader-Willi syndrome than in the general population. It means one patient, on a combination of three different drugs plus structured lifestyle support over a much longer period (18 months versus the trial's 48 weeks), had an outcome well outside the range seen in the trial population the drug has actually been tested in. Retatrutide also remains investigational: it has not completed the Phase 3 program that would normally precede any approval, and the semaglutide and dulaglutide the patient later used are the only approved incretin medicines in this sequence.^[3]

What this case report does not show

It does not show that retatrutide, or GLP-1 therapy generally, is an effective or approved treatment for Prader-Willi syndrome. Retatrutide has not been approved by the FDA, EMA, MHRA or any national regulator for any indication, so its use here sat outside any approved label. It is one patient, with no control group, no comparison arm and no way to separate the individual effect of retatrutide, oral semaglutide and dulaglutide from each other or from the diet and exercise program that ran alongside all three.

Case reports like this one are hypothesis-generating, not evidence of what will happen for other people with PWS. A rare genetic condition can also produce an unusually strong or unusually poor response that has little to do with the drug and more to do with that individual's biology. The authors themselves frame the paper as a single case, not a treatment protocol, and 18 months is not long enough to know whether the weight loss and diabetes remission will hold.

What this means

The result is worth watching. It is the kind of single-patient signal that sometimes leads to a small pilot trial in a rare disease with few good treatment options. It is not, on its own, a reason for anyone with Prader-Willi syndrome or their family to seek out retatrutide, which remains an investigational compound with no lawful general prescribing route. Anyone considering incretin-based therapy for PWS, whether retatrutide, semaglutide or another option in the class, should raise it with a clinician who knows the person's full medical history and can weigh a treatment that has not been studied for this condition in any controlled trial.